You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 367 A phase 1/1b dose-escalation study of intravenously administered SB 11285 alone and in combination with atezolizumab in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
367 A phase 1/1b dose-escalation study of intravenously administered SB 11285 alone and in combination with atezolizumab in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to August 2024

AbstractFullPdf
Nov 2020133021
Dec 20202605
Jan 20211402
Feb 20211302
Mar 20212804
Apr 20211807
May 2021202
Jun 2021006
Jul 2021009
Aug 2021008
Sep 2021005
Oct 202110021
Nov 202126018
Dec 20211203
Jan 20221404
Feb 20222606
Mar 20223405
Apr 20224204
May 20223201
Jun 20222204
Jul 20223403
Aug 20224809
Sep 20225802
Oct 20223006
Nov 20223805
Dec 20225004
Jan 20233403
Feb 20235201
Mar 20234209
Apr 20232004
May 20231802
Jun 20233200
Jul 20237006
Aug 20233405
Sep 20234805
Oct 20233809
Nov 20234805
Dec 20236001
Jan 2024802
Feb 20243600
Mar 20247005
Apr 20245202
May 20243402
Jun 20243002
Jul 20245601
Aug 20247004
Total15620234